Skip to content
Pep My LifePeptides, decoded for real life.

KPV · Research breakdown

What the KPV research actually says

Every study, translated. This is the depth behind the KPV overview — read it if you want the receipts.

Last reviewed September 3, 20269 sources
Back to the plain-English KPV overview

How strong is the evidence, dimension by dimension?

Interesting biology. No human clinical evidence base.

Overall evidence

Preclinical

Consistent experimental findings, no human clinical base underneath them.

Preclinical evidence

Substantial preclinical research

Multiple independent cell and rodent models, especially in gut inflammation.

Mechanistic understanding

Plausible and partly described

PepT1-mediated uptake gives a credible route into the cells where the effects were seen.

Evidence by route

These are graded separately on purpose. Evidence from one route of administration does not carry over to another.

Human cell evidence

Human cells, not people

Keratinocyte work gives mechanistic information. It is not a clinical study.

Human clinical evidence

None identified

FDA reported no identified clinical studies or human exposure data by any route.

Human cell research is graded separately from human clinical research on purpose. Cells taken from people are still cells — treating keratinocyte findings as human evidence is the single easiest way to overstate what is known about KPV.

How we grade evidence

Here's the reality check.

In FDA's 2026 review of KPV for pharmacy compounding, the agency said it had not identified clinical studies or human exposure data for KPV via any route of administration. It also said potential safety risks in humans remain unknown.

clinical studies or human exposure data identified by FDA
0clinical studies or human exposure data identified by FDA

Sources78

Gut inflammation and PepT1

Preclinical

The strongest thread in the KPV literature. Two 2008 papers established both a plausible route into the relevant cells and repeated anti-inflammatory effects in rodent colitis models.

Animal

PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation

Dalmasso G, et al. · Gastroenterology 2008 134(1):166–178

PMID 18061177DOI 10.1053/j.gastro.2007.10.026PMCID PMC2431115

Study type
Intestinal epithelial and immune cell models plus mouse colitis models

What researchers did

Tested whether KPV could enter intestinal epithelial and immune cells via the PepT1 transporter, and what happened to inflammatory signalling once it did. The work spans cell models and mouse colitis models.

What they found

KPV was taken up through PepT1 and was associated with reduced inflammatory signalling in the cell models, with reduced inflammation reported in mouse colitis.

What that actually tells us

There is a credible mechanism — a specific transporter that gets KPV into the cells where the effects were observed — behind the anti-inflammatory signal.

What it doesn't tell us

Nothing about people. These are cell and mouse experiments; they do not establish that KPV treats intestinal inflammation in humans, at any dose or by any route.

Animal

Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease

Kannengiesser K, et al. · Inflammatory Bowel Diseases 2008

PMID 18092346

Study type
Two murine colitis models

What researchers did

Assessed KPV's anti-inflammatory potential across two separate mouse models of inflammatory bowel disease.

What they found

The investigators reported significant anti-inflammatory effects in both murine colitis models.

What that actually tells us

The gut signal is not a one-off. It reproduced across more than one model, which is why the area kept attracting research.

What it doesn't tell us

It does not translate into efficacy in human inflammatory bowel disease. Mouse colitis models are a screening tool, not a stand-in for patients.

Sources12

Inflammatory signalling

Mechanistic

The proposed mechanism is about turning down the signals cells use to coordinate an inflammatory response.

NF-κB and MAP kinase pathways

Researchers have reported effects on inflammatory pathways including NF-κB and MAP kinase signalling in experimental models. These are central coordinators of inflammatory responses, which is what makes the finding interesting.

Inflammatory cytokine activity

Reductions in inflammatory cytokine activity have been reported alongside the pathway effects, in the same experimental systems.

Pathway effects are not outcomes

Every result in this section is pathway-level and experimental. Showing that a compound moves an inflammatory signal in a model is a reason to keep investigating, not a demonstration that it treats an inflammatory condition in a person.

Sources12

Wound and repair research

Preclinical

A separate and much narrower research thread, in a single tissue and a single species.

AnimalTopical

Effects of the COOH-terminal tripeptide alpha-MSH(11–13) on corneal epithelial wound healing: role of nitric oxide

Bonfiglio V, et al. · Experimental Eye Research 2006

PMID 16965771

Study type
Rabbit corneal epithelial wound model
Route
Topical

What researchers did

Applied the tripeptide topically to the eye in a rabbit corneal epithelial wound model and tracked repair.

What they found

Topical application was associated with faster corneal epithelial repair after injury.

What that actually tells us

There is a tissue-repair signal, in one tissue, in one species, applied topically.

What it doesn't tell us

It says nothing about injectable KPV, nothing about repair elsewhere in the body, and nothing about humans. Corneal epithelium is not a general model for human tissue.

Sources3

Human cell research

Mechanistic

Cells taken from humans are still cells. This section exists partly to keep that distinction visible.

This is not human clinical evidence

A human cell culture tells you what a compound does to cells in a dish. It has no circulation, no immune system and no barrier tissue. Pep My Life grades this separately from human clinical research for exactly that reason.

Cell / in vitroHuman cells

Lysine-Proline-Valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-κB pathway

Sung J, Ju S-Y, Park S, Jung W-K, Je J-Y, Lee S-J. · Tissue and Cell 2025 95:102837

PMID 40073467DOI 10.1016/j.tice.2025.102837

Study type
Human keratinocyte models exposed to particulate pollution
Route
Human cells

What researchers did

Examined KPV in human keratinocyte models exposed to particulate pollution.

What they found

Reported changes involving inflammatory signalling and oxidative stress.

What that actually tells us

Useful mechanistic information from human cells, which is a step closer to relevance than a rodent model.

What it doesn't tell us

It is not a clinical trial and must not be described as human evidence for any outcome.

Sources4

Can KPV be delivered orally?

Preclinical

Recent work highlights a question the popular discussion mostly skips: whether KPV survives the trip when taken by mouth.

An engineered system is not the same product

The study below built a conjugate designed to release KPV at inflamed tissue. It does not establish that ordinary oral KPV has the same stability, absorption, distribution or effect.

AnimalOral (engineered conjugate)

Inflammation-triggered self-immolative conjugates enabling oral peptide delivery

Cheng J, et al. · 2026

PMID 41533788

Study type
Mouse colitis models and a mouse acute-lung-injury model
Route
Oral (engineered conjugate)

What researchers did

Developed an engineered inflammation-triggered oral KPV conjugate — a prodrug system designed to release the peptide where inflammation is present — and tested it in mouse models.

What they found

The engineered system accumulated more strongly in inflamed colon tissue and showed greater effects than free KPV. Accumulation and effects were also reported in a mouse acute-lung-injury model.

What that actually tells us

That delivery is a real obstacle researchers are actively engineering around — and that free KPV performed less well than the engineered construct in these models.

What it doesn't tell us

It does not tell us how commercially sold oral KPV behaves. If anything it points the other way: the engineering existed because plain delivery was the problem.

Sources5

KPV vs modified KPV

A distinction worth holding onto when reading anything about this peptide.

Related is not identical

Researchers have studied modified peptides based on the KPV sequence too, such as (CKPV)₂. Those results are interesting, but they are not automatically evidence for plain KPV — and findings from modified derivatives, including antimicrobial ones, should not be attributed to KPV itself.

What has actually been studied in people?

Mechanistic

Nothing we can point to. FDA's 2026 scientific review of KPV for pharmacy compounding reported that it had not identified the human data that would normally exist for a substance discussed this widely.

What FDA reported it did not identify

  • Human pharmacokinetic studies
  • Human clinical studies
  • Human exposure data
  • Human case reports
  • Human studies assessing immunogenicity or aggregation

An absence of identified data is not a finding of harm. It is an absence of the evidence needed to describe safety or effectiveness with confidence.

Sources789

Regulatory status

KPV was reviewed by FDA's Pharmacy Compounding Advisory Committee in July 2026 as a substance being considered for the Section 503A Bulks List. The committee narrowly voted in favour of recommending KPV-related bulk substances for inclusion.

What that vote is and is not

FDA advisory committee recommendations are non-binding. Inclusion on a compounding bulks list would not make KPV an FDA-approved drug, and the vote is not a finding that KPV is safe or effective. Secondary news coverage reported the vote margin; FDA's own meeting materials are the authoritative source for status.

Sources67

What we know, and what we don't

What we know

  • KPV is Lys-Pro-Val, the C-terminal tripeptide of alpha-MSH.
  • It has repeatedly demonstrated anti-inflammatory activity in experimental systems.
  • Gut and inflammatory-bowel models are one of its strongest preclinical research areas.
  • PepT1-mediated uptake provides a plausible mechanism in intestinal and immune cell models.
  • Researchers continue to investigate KPV and engineered KPV delivery systems.

What we don’t know

  • Whether KPV meaningfully reduces inflammatory disease in humans.
  • Whether injectable KPV is effective.
  • Long-term human safety.
  • Human pharmacokinetics.
  • Whether ordinary oral KPV behaves like engineered experimental oral delivery systems.
  • A validated human regimen.
  • Whether effects seen in topical, cellular or animal research translate across other routes.

References

  1. Animal

    PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation

    Dalmasso G, et al. · Gastroenterology 2008 134(1):166–178

    PMID 18061177DOI 10.1053/j.gastro.2007.10.026PMCID PMC2431115

    PepT1-mediated uptake into intestinal and immune cells, with reduced inflammatory signalling and reduced inflammation in mouse colitis.

  2. Animal

    Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease

    Kannengiesser K, et al. · Inflammatory Bowel Diseases 2008

    PMID 18092346

    Significant anti-inflammatory effects reported in two murine colitis models.

  3. AnimalTopical

    Effects of the COOH-terminal tripeptide alpha-MSH(11–13) on corneal epithelial wound healing: role of nitric oxide

    Bonfiglio V, et al. · Experimental Eye Research 2006

    PMID 16965771

    Faster corneal epithelial repair after injury in a rabbit model.

  4. Cell / in vitroHuman cells

    Lysine-Proline-Valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-κB pathway

    Sung J, Ju S-Y, Park S, Jung W-K, Je J-Y, Lee S-J. · Tissue and Cell 2025 95:102837

    PMID 40073467DOI 10.1016/j.tice.2025.102837

    Changes involving inflammatory signalling and oxidative stress in human keratinocyte models exposed to particulate pollution. Human keratinocyte / 3D skin-model research, not a human clinical trial.

  5. AnimalOral (engineered conjugate)

    Inflammation-triggered self-immolative conjugates enabling oral peptide delivery

    Cheng J, et al. · 2026

    PMID 41533788

    Engineered oral conjugate accumulated in inflamed colon tissue and outperformed free KPV in mouse models.

  9. Regulatory source

    Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks — KPV entry

    U.S. Food and Drug Administration

    States that FDA has not identified human exposure data for KPV administered by any route.

Looking for the short version instead?

Read the KPV overview →

Stay current

New research, decoded and sent to you

Occasional emails when we publish something worth your time. No hype, no product pitches.

Signup opens soon.